European Union Cannabis and Hemp Vape Sustainability Policy Proposals Report 2022 – ResearchAndMarkets.com

By -
DUBLIN--(BUSINESS WIRE)--The "Sustainability policy proposals affecting the cannabis and hemp-derived vape sector in the EU" report has been added to ResearchAndMarkets.com's offering. In the EU the cannabis and hemp-derived vape industry is increasingly under regulatory compliance pressure with new rules that introduce obligations. Not only will companies be required to adapt to a new framework that applies to all other industries, but industry-specific negative environmental externalities and greenwashing techniques are in the spotlight more and more. In this report, the analyst has identified the 11 EU initiatives we consider to be the most impactful for the sector. According to our analysis, among the initiatives we are tracking, the new rules on batteries, plastics, and electronics are likely to substantially increase the regulatory burden on the sector. Key Topics Covered: 1 Executive Summary 2 Scope of this Report 3 EU Sustainability Policy Agenda 4 Overview of Sustainability and the Cannabis and Hemp-derived Vape Sector For more information about this report visit https://www.researchandmarkets.com/r/9w9618
http://dlvr.it/SbhM5p

Comments

Post a Comment

Popular posts from this blog

Hempy 2014!

By -
Image
I started 2013 with a basement full of weed and an empty bank account. I don’t know of any Seattle growers that actually got rich from growing pot this year. I think a lot of us unemployed corporate types who were laid off saw the opportunity to work for ourselves until the state could figure out what to do with the future of medical and voter approved recreational pot. A year later, the future of  medical marijuana in Washington State is still tenuous.  I have personally witnessed healing in people who use cannabis as medicine and I think it’s a crime that providers have been thrown in jail for helping others. Cannabis IS medicine and we have a God-given right to have access to it. Dispensary “donations” were my main source of income in 2013. I make half of what I used to back in my VC-funded days, but I don’t care. Money is not it. Helping people, and loving what you do on a daily basis where it’s at, man. The meaning of life is to be of service to others. Working
Read more

Coming Out of the Pot Closet

By -
Image
I have to vacuum before my mother arrives from Arizona. I’m 40-something years old and I still want her housekeeping approval. While we’re close, and speak on the phone every week, we haven’t seen each other 1:1 for a while. I’m freaking out because I think she’ll have an aneurysm when I tell her how I’ve been paying my bills the past three years. Garden of Eve The time has arrived for me to come out of the Pot Closet to my mother. How did I get here? I was laid off from my event-planning job while dating a “normal-looking” guy, who owned his own landscaping business. “Larry” also happen to own a basement full of marijuana plants for extra spending money (on prostitutes, as it turns out, but that’s a different blog post). He taught me everything I know about being a Pharmer -- from cloning and transplanting, to providing my babies with the proper nutrients and watering techniques.  I learned a lot – about the miraculous cannabis plant, and about the lying, cheating asshol
Read more

PureTech Provides End of Year Report on Key Progress

By -
Image
BOSTON--(BUSINESS WIRE)--PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (“PureTech” or the “Company”), a clinical-stage biotherapeutics company dedicated to changing the treatment paradigm for devastating diseases, today reported on the key progress made across its Wholly Owned Programs1 and Founded Entities2 in 2022. Daphne Zohar, Founder and Chief Executive Officer of PureTech, commented: “2022 has been a particularly successful and productive year in both crystallizing value and shaping the future of PureTech. Our primary focus is to progress our Wholly Owned Pipeline to commercialization and deliver new classes of medicines for patients with serious, debilitating conditions. We are advancing toward this goal by deepening our commitment to programs with compelling clinical data that are moving into late-stage studies and that we believe have the potential for broad impact. “Over the next 12 months, we anticipate multiple important catalysts that will further guide how we prioritize o
Read more